WO2000067766A1 - Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina - Google Patents
Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina Download PDFInfo
- Publication number
- WO2000067766A1 WO2000067766A1 PCT/RU1999/000480 RU9900480W WO0067766A1 WO 2000067766 A1 WO2000067766 A1 WO 2000067766A1 RU 9900480 W RU9900480 W RU 9900480W WO 0067766 A1 WO0067766 A1 WO 0067766A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- πρedelaχ
- πρeπaρaτa
- venom
- οτnοsheniyu
- vybiρayuτ
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 5
- 230000001172 regenerating effect Effects 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000002435 venom Substances 0.000 claims abstract description 19
- 210000001048 venom Anatomy 0.000 claims abstract description 19
- 231100000611 venom Toxicity 0.000 claims abstract description 19
- 231100000614 poison Toxicity 0.000 claims abstract description 16
- 239000002574 poison Substances 0.000 claims abstract description 16
- 239000012535 impurity Substances 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 3
- 241001465754 Metazoa Species 0.000 claims abstract 2
- 238000002347 injection Methods 0.000 claims description 20
- 239000007924 injection Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 241000699670 Mus sp. Species 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000009434 installation Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 11
- 239000003995 emulsifying agent Substances 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 206010029240 Neuritis Diseases 0.000 abstract 1
- 201000009859 Osteochondrosis Diseases 0.000 abstract 1
- 206010037779 Radiculopathy Diseases 0.000 abstract 1
- 241001442055 Vipera berus Species 0.000 abstract 1
- 241001442069 Vipera berus berus Species 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 230000003137 locomotive effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010061928 radiculitis Diseases 0.000 abstract 1
- 239000003998 snake venom Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 12
- 239000002253 acid Substances 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940035674 anesthetics Drugs 0.000 description 4
- 239000003193 general anesthetic agent Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000009172 bursting Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000012432 gingerbread Nutrition 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Definitions
- the invention is subject to the field of medicine and may be used, for example, in the case of a pharmaceutical-regenerative drug, and the treatment of using it
- Reactive-regenerative drugs are known that contain active components on basic active components and omnipotent components [1].
- the product has been found to be biologically active, which contains biologically active substances that are harmful to the body.
- Izves ⁇ en s ⁇ s ⁇ b izg ⁇ vleniya ⁇ e ⁇ a ⁇ a ⁇ ivn ⁇ - ⁇ egene ⁇ a ⁇ ivn ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a, v ⁇ lyuchayuschy ⁇ dg ⁇ v ⁇ u is ⁇ dny ⁇ ⁇ m ⁇ nen ⁇ v, i ⁇ vzaim ⁇ svyazyvanie with ⁇ m ⁇ schyu ⁇ as ⁇ v ⁇ i ⁇ elya and d ⁇ ugi ⁇ ⁇ m ⁇ nen ⁇ v, and ⁇ chis ⁇ u ⁇ es ⁇ i ⁇ vanie g ⁇ v ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a [1].
- Izves ⁇ en s ⁇ s ⁇ b izg ⁇ vleniya ⁇ e ⁇ a ⁇ a ⁇ ivn ⁇ - ⁇ egene ⁇ a ⁇ ivn ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a, v ⁇ lyuchayuschy ⁇ dg ⁇ v ⁇ u is ⁇ dny ⁇ ⁇ m ⁇ nen ⁇ v, i ⁇ vzaim ⁇ svyazyvanie with ⁇ m ⁇ schyu ⁇ as ⁇ v ⁇ i ⁇ elya, and emulga ⁇ a ⁇ nse ⁇ van ⁇ a, and ⁇ chis ⁇ u ⁇ es ⁇ i ⁇ vanie g ⁇ v ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a [3] - ⁇ i ⁇ .
- Distinctive features of the method are included in that, as a part of the accessory, an empty anesthetics is removed.
- the distributor - distilled water in the process of its preparation reduces the cost of salted acid, thereby avoiding the concentration of saline acid. They mix the prepared components and homogenize the mixture, achieving a total volume of 0.3 ml of non-mixed components, the components are mixed. For a volume of 5 ml of the whole mixture.
- the distributor - distilled water in the process of its preparation acidifies the saline acid. Ensuring the concentration of saline acid is equal to 1%. Mix the prepared components and homogenize the mixture, achieving a total volume of 0.2 ml of non-homogenized mixture of 5 ml of the mixture.
- the distributor - distilled water in the process of its preparation reduces the cost of salted acid, thereby avoiding the concentration of saline acid.
- Example 1 Patient G. 46 years old weighing 104 kg. Diagnosis: interstitial disease (herniation 4-5 calls), compression of the cerebral cortex at this level, which is growing at an accident.
- drugs For the treatment of drugs, they are administered cyclically in 17 stages with a total of 62 injections. For each of these stages, 4–6 injections are given. Injections are administered internally to a depth of 4 mm, and when administered to a depth of 6 mm, the maximum injection depth is 13 mm.
- the injection area is selected in this case as equal to 4 cm 2 for an area of 24 cm for a large patient’s area of 0.5 patient.
- For treatment they use a total of 14.5 mg of the drug.
- anesthetics an equal of 10 mg is taken and ⁇ is equal to 0.8.
- Example 2 Patient P. 33 years old weighing 80 kg. Diagnosis: atrial perennial, simple auto-herniation of intervertebral disc with a size of 13 mm, expressed by acute pain syndrome.
- drugs they are administered cyclically in 25 stages with a total of 100 injections. For each of these steps, 4–8 injections are given. Injections are administered internally to a depth of 4 mm, and when administered to a depth of 6 mm, the maximum injection depth is 13 mm.
- the injection area is selected in this example as equal to 6 cm 2 for the area of 6 cm 2 for a large patient’s body at a rate of 0.6.
- 18.3 mg of the drug is used in its entirety. With this dose of anesthetics, an equal of 15 mg is taken.
- Example 3 Bolnoy ⁇ . 40 years old weighing 92 kg. Diagnosis: hernia 4-5 intercostal disc with a size of 17 mm, expressed by acute pain syndrome. For treatment eleven
- the drugs are administered cyclically in 25 stages with a total of 100 injections. For each of these stages, 4–8 injections are given. Injections are administered internally to a depth of 4 mm, and when administered to a depth of 6 mm, the maximum injection depth is 13 mm.
- the injection area is selected in this case as equal to 6 cm for the area of 6 cm for the patient's body at a pressure of 0.6.
- For treatment they use the whole final dose of 20.4 mg of the drug. With this dose of anesthetics, an equal of 17 mg is taken.
- ⁇ izhnie and ve ⁇ nie values were zayavlenny ⁇ ⁇ edel ⁇ v ⁇ lucheny on ⁇ sn ⁇ ve s ⁇ a ⁇ is ⁇ iches ⁇ y ⁇ b ⁇ ab ⁇ i ⁇ ezul ⁇ a ⁇ v e ⁇ s ⁇ e ⁇ imen ⁇ alny ⁇ issled ⁇ vany, analysis and ⁇ b ⁇ bscheniya i ⁇ and izves ⁇ ny ⁇ of ⁇ ubli ⁇ vanny ⁇ is ⁇ chni ⁇ v readyy ⁇ , is ⁇ dya of usl ⁇ viya d ⁇ s ⁇ izheniya u ⁇ azann ⁇ g ⁇ ⁇ e ⁇ niches ⁇ g ⁇ ⁇ ezul ⁇ a ⁇ a and is ⁇ lz ⁇ vaniem ⁇ a ⁇ a iz ⁇ b ⁇ e ⁇ a ⁇ els ⁇ y in ⁇ uitsii.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention se rapporte au domaine de la médecine et notamment au traitement de troubles du système locomoteur tels que l'ostéochondrose, la radiculite, la radiculonévrite, l'arthrite et l'arthrose. Cette invention concerne une préparation réparatrice et régénératrice qui comprend un composant bioactif à base d'un poison animal, un solvant, un émulsifiant, un conservateur ainsi que des impuretés de ballastage tolérées. Le poison consiste en du venin provenant essentiellement de vipère commune (vipera berus berus). Le procédé de fabrication de cette préparation réparatrice et régénératrice consiste à préparer les composants de départ, à les lier à l'aide du solvant, de l'émulsifiant et du conservateur, puis à purifier et à tester le produit fini. La lyophilisation et la cristallisation du venin de vipère commune se font en maintenant, dans un local industriel, une température T1 qui se situe dans la plage 1,9 ≤ (zT1+T2)/T2 ≤ 2,1 (température en degrés K) où z représente un coefficient expérimental choisi en fonction de la saison de prélèvement du venin et de la teneur en humidité de celui-ci, et se situe dans la plage 0,28 ≤ z ≤ 1,6. Cette invention concerne également un procédé d'utilisation thérapeutique de cette préparation réparatrice et régénératrice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU30858/00A AU3085800A (en) | 1999-05-05 | 1999-12-10 | Restorative and regenerative preparation, method for producing the same and therapeutical use according to l.v. dubinina |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU99108706A RU2146146C1 (ru) | 1999-05-05 | 1999-05-05 | Репаративно-регенеративный препарат, способ его изготовления и лечебного использования по л.в.дубининой |
| RU99108706 | 1999-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2000067766A1 true WO2000067766A1 (fr) | 2000-11-16 |
Family
ID=20219074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU1999/000480 WO2000067766A1 (fr) | 1999-05-05 | 1999-12-10 | Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3085800A (fr) |
| RU (1) | RU2146146C1 (fr) |
| WO (1) | WO2000067766A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2261719C2 (ru) * | 2000-10-27 | 2005-10-10 | Писарев Александр Геннадьевич | Водно-спиртовая настойка |
| WO2003075936A1 (fr) * | 2002-03-11 | 2003-09-18 | Nina Alexandrovna Karagoujova | Procede d'elevage des serpents pour obtenir des composants de poison |
| RU2266746C2 (ru) * | 2004-03-12 | 2005-12-27 | Закрытое Акционерное Общество "Лорр" | Средство для лечения невралгических заболеваний |
| RU2276987C2 (ru) * | 2004-03-30 | 2006-05-27 | Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) | Способ иммунобиохимической коррекции организма крупного рогатого скота |
| RU2355407C1 (ru) * | 2008-01-09 | 2009-05-20 | Юрий Антонович Кошелев | Средство для профилактики и лечения заболеваний опорно-двигательного аппарата |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4126676A (en) * | 1977-07-22 | 1978-11-21 | Sanders Murray J | Modified neurotoxin derived from naja genus snake venom |
| RU2093160C1 (ru) * | 1991-07-24 | 1997-10-20 | Бейреш Экспорт-Импорт РТ | Фармацевтическая композиция и способ воздействия на ретикулоэндотелиальную систему, лечения муковисцидоза и хронических болевых синдромов, сопровождающих заболевания опорно-двигательного аппарата и онкологические заболевания |
| RU2106863C1 (ru) * | 1996-12-27 | 1998-03-20 | Лариса Васильевна Дубинина | Способ лечения заболеваний опорно-двигательного аппарата и периферической нервной системы по л.в.дубининой |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3888977A (en) * | 1973-02-01 | 1975-06-10 | Murray J Sanders | Modified neurotoxin |
| RU2088216C1 (ru) * | 1994-07-04 | 1997-08-27 | Саратовский научно-исследовательский институт травматологии и ортопедии | Средство для лечения ревматоидного артрита |
-
1999
- 1999-05-05 RU RU99108706A patent/RU2146146C1/ru active
- 1999-12-10 AU AU30858/00A patent/AU3085800A/en not_active Abandoned
- 1999-12-10 WO PCT/RU1999/000480 patent/WO2000067766A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4126676A (en) * | 1977-07-22 | 1978-11-21 | Sanders Murray J | Modified neurotoxin derived from naja genus snake venom |
| GB2001244A (en) * | 1977-07-22 | 1979-01-31 | Sanders M | Neurotoxin derived from naja genus snake venom |
| RU2093160C1 (ru) * | 1991-07-24 | 1997-10-20 | Бейреш Экспорт-Импорт РТ | Фармацевтическая композиция и способ воздействия на ретикулоэндотелиальную систему, лечения муковисцидоза и хронических болевых синдромов, сопровождающих заболевания опорно-двигательного аппарата и онкологические заболевания |
| RU2106863C1 (ru) * | 1996-12-27 | 1998-03-20 | Лариса Васильевна Дубинина | Способ лечения заболеваний опорно-двигательного аппарата и периферической нервной системы по л.в.дубининой |
Non-Patent Citations (1)
| Title |
|---|
| MASHKOVSKY M.D.: "Lekarstevennye sredstva m.", MEDITSINA, 1993, pages 415 - 416 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2146146C1 (ru) | 2000-03-10 |
| AU3085800A (en) | 2000-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1120458A (zh) | 生理活性肽组合物 | |
| JPH06503835A (ja) | ピートから誘導した生物活性生成物、ならびにこの生物活性生成物を含有する製剤組成物および化粧品組成物 | |
| TW200911279A (en) | Compositions, uses, and method of making wound care products from naturally occurring food ingredients | |
| RU2112504C1 (ru) | Средство для лечения заболеваний предстательной железы "витапрост" | |
| RU2200564C1 (ru) | Лекарственная форма пантогематогена на гелевой основе | |
| DE69528048T2 (de) | Peptid oder protein enthaltende hyaluronsäure mit niedrigem molekulargewicht | |
| RU2036651C1 (ru) | Биогенный стимулятор для лечения и профилактики заболеваний сельскохозяйственных животных | |
| WO2000067766A1 (fr) | Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina | |
| WO1994028153A2 (fr) | Adn de faible masse moleculaire tiree de laitance d'esturgeon, procede d'obtention de l'adn et preparation pharmaceutique a base de celui-ci | |
| WO2001064228A1 (fr) | Procede de production d'une substance biologiquement active a partir du serum sanguin | |
| CN111569044A (zh) | 一种含紫球藻多肽的组合物及其制备方法 | |
| RU2070409C1 (ru) | Препарат для лечения мастита у лактирующих животных | |
| RU2350342C1 (ru) | Способ изготовления геля на основе водного экстракта из пантов | |
| CN107596355A (zh) | 一种医用镇痛、消肿、退热的外用凝胶剂及其制备方法 | |
| WO1995008318A2 (fr) | Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse | |
| WO1992006696A1 (fr) | Procede d'obtention d'une preparation bioactive a partir du sang | |
| CN113501869A (zh) | 具有创面修复作用的肽 | |
| RU2089197C1 (ru) | Препарат пролонгированного действия и способ его получения | |
| US4323496A (en) | Innoxious interferon-inducing substance, inducing agent and process for producing same | |
| RU2074727C1 (ru) | Способ лечения и профилактики желудочно-кишечных заболеваний телят и поросят | |
| HUP0301119A2 (hu) | Bioaktiváló hatóanyag és gyógyszerkészítmény | |
| WO2001012201A1 (fr) | Composition remplacant le plasma sanguin | |
| WO2001058464A1 (fr) | Forme posologique d'ivermectine a dispersion aqueuse utilisee pour soigner ectoparasitose et endoparasitose | |
| RU2769508C2 (ru) | Способ получения комбинированного препарата из плаценты животных и фитосырья | |
| EP0393190A4 (en) | Copolymers of vinyl alcohol with vinyl acetate, cross-linked by glutaric dialdehyde, method of obtaining them and a phramaceutical preparation based thereon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |